Infertility
Conditions
Keywords
GnRH agonist, GnRH antagonist, IVF, ICSI, assisted reproduction, luteal phase
Brief summary
GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the fixed GnRH antagonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.
Interventions
single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
DRUGNaCl %0.9
0.1 ml sterile saline sc injection 3 days after embryo transfer
Sponsors
V.K.V. American Hospital, Istanbul
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol, oocyte pick-up and ICSI. * Embryo transfer performed on day 3
Exclusion criteria
* Participation in another trial that was being conducted in our unit at the same time. * Preimplantation genetic screening cycles. * Day 5 embryo transfers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ongoing pregnancy beyond 20th gestational week | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical pregnancy rate | — |
| Embryo implantation rate | — |
Countries
Turkey (Türkiye)
Outcome results
None listed